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1. Introduction
The myriad of  different  post-translation modifications  (PTMs)  of  proteins  augments  the
information encoded by the human genome,  from about  25,000 genes to  over  1  million
proteins  that  compose  the  human  proteome  [1,  2].  PTMs  involve  the  chemical
modification of target amino acid residues and, among others,  include the addition of a
methyl  group  to  arginine  residues,  or  arginine  methylation,  which  is  one  of  the  most
extensive  protein  modifications  occurring  in  mammalian  cells.  During  the  last  years,
arginine  methylation  has  attracted  growing  attention  due  to  its  impact  on  cellular
function.  Attesting to  its  biological  importance,  protein  arginine  methylation appears  to
be an evolutionarily  ancient  modification.  Arginine  methylation is  now recognized as  a
widespread  PTM  that  occurs  on  multiple  classes  of  proteins  with  distinct  cellular
localizations.  The  arginine  residue  is  unique  among  amino  acids,  since  its  guanidine
group contains five potential hydrogen bond donors (Figure 1) positioned for interactions
with  hydrogen bond acceptors  as  DNA,  RNA and proteins.  Each  addition  of  a  methyl
group  removes  a  hydrogen  donor,  so  the  methylation  of  arginine  residues  in  proteins
will  readily  modulate  their  binding  interactions  and  thus  their  physiological  functions.
Here, we provide an introduction to protein arginine methylation and discuss the current
state  of  knowledge  regarding  this  modification  in  mammals.  In  addition,  we  provide
insight into how protein arginine methylation relates with the homocysteine metabolism.
Lastly,  we  briefly  discuss  how  protein  arginine  methylation  may  be  disturbed  in  the
context of hyperhomocysteinemia, sharing some of our recent results.
© 2013 Esse et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 1. Methylation of the arginine side chain in proteins by protein arginine methyltransferases (PRMTs). The argi‐
nine residue holds 5 potential hydrogen bond donors. Mammalian PRMTs use the methyl group from a molecule of S-
adenosyl-L-methionine (AdoMet) to form ω-NG-monomethylarginine (MMA). Subsequently, type I PRMTs add a
methyl group to the same nitrogen atom forming ω-NG,NG-dimethylarginine (ADMA), whereas type II PRMTs generate
ω-NG,N’G-dimethylarginine (SDMA).
2. The mammalian PRMTs: A brief overview
Methylation of arginine is catalyzed by protein arginine methyltransferases (PRMTs).
PRMTs catalyze the transfer of methyl groups from the universal methyl donor, S-adenosyl-
L-methionine (AdoMet), to the guanidine nitrogen atom of the target arginine residues with‐
in proteins [3].
The first documented protein with arginine methylation activity, then termed protein meth‐
ylase I, was purified from calf thymus [4, 5]. Additional family members were subsequently
identified and purified from different tissues and cell lines [6-16]. In mammals, PRMTs are
grouped in two major classes: type I and type II. Both PRMT types catalyze the transfer of a
single methyl group from AdoMet to an arginine residue in the target protein, producing ω-
NG-monomethylarginine (MMA) (Figure 1). However, differences exist when adding the
second methyl group: type I members add it on the same previously methylated nitrogen,
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forming ω-NG,NG-dimethylarginine (ADMA), whereas type II members add it to the other
N-terminal nitrogen of the arginine residue, yielding ω-NG,N’G-dimethylarginine (SDMA).
Therefore, three distinct types of methylated arginine residues (MMA, ADMA and SDMA)
are present on a horde of different proteins in the cytosol, nucleus and organelles of mam‐
malian cells, ADMA being the most prevalent [3].
Figure 2. Schematic representation of the human protein arginine methyltransferase (PRMTs) family. For each mem‐
ber, the length of the longest isoform is indicated on the right. All members of the family possess at least one con‐
served MTase domain with signature motifs I, post-I, II, and III and a THW loop. Additional domains are marked in
yellow boxes: SH3, ZnF (zinc finger), Myr (myristoylation), F-box, TPR (tetratricopeptide) and NosD (nitrous oxidase ac‐
cessory protein). Adapted from [17].
To  date,  the  human  PRMT  family  includes  eleven  enzymes,  termed  from  PRMT1  to
PRMT11.  Six  are  classified  as  type  I  (PRMT1,  PRMT2,  PRMT3,  PRMT4,  PRMT6  and
PRMT8),  and  two  as  type  II  (PRMT5  and  PRMT9).  The  classification  of  PRMT7  is
controversial,  as  described  below.  The  remaining  two  proteins,  PRMT10  and  PRMT11,
were identified by their homology with PRMT7 and PRMT9, respectively, but their PRMT
activity has not been sustained by experimental evidence [18, 19]. The genes encoding the
different  PRMTs  are  all  located  on  different  chromosomes,  except  the  ones  coding  for
PRMTs  1  and  4,  which  are  both  located  in  chromosome  19.  Different  splice  variants
coding for the corresponding isoforms are recognized for all PRMTs. Moreover, different
cellular localizations are observed among them.
Although the human PRMT members vary in length from 316 to 956 amino acid residues,
they all  contain a highly conserved catalytic  core region of  around 300 residues (Figure
2).  However,  each  PRMT  presents  a  unique  N-terminal  region  of  variable  length  and
distinct domain motifs, as for example PRMT3 and PRMT8 that bear a zinc finger (ZnF)
and  a  myristoylation  domain,  respectively.  Interestingly  PRMT7 and  PRMT10  exhibit  a
second  catalytic  domain.  Until  present,  only  the  3D  structures  of  PRMT1,  PRMT3  and
PRMT5 were solved by X-ray crystallography [20-22]. These structures revealed that, also
at  the  structural  level,  the  catalytic  core  is  highly  conserved.  Three  structural  regions
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were identified, namely, a methyltransferase (MTase) domain, a β-barrel  domain unique
to  the  PRMT  family  and  a  dimerization  arm.  The  MTase  domain  is  located  in  the  N-
terminal  region  of  the  catalytic  core.  It  consists  of  a  α/β  Rossmann  fold,  typical  of
AdoMet-dependent  methyltransferases,  containing  the  conserved motifs  I,  post-I,  II  and
III [23]. Motif I includes in its C-terminal part the signature sequences for most classes of
MTases (GxGxG) involved in AdoMet binding. A relevant structural element localized in
the MTase domain is the double-E loop (containing two invariant glutamate (E) residues).
The C-terminal part of the catalytic core is a β-barrel domain containing 10 β-strands and
a THW (threonine-histidine-tryptophan) loop (the most highly conserved sequence of this
domain). Within the overall structure, the THW loop is located next to the double-E loop
in the AdoMet binding domain, forming the active site. The dimerization arm is formed
by  a  three-helix  segment,  which  is  inserted  between  strands  6  and  7  of  the  β-barrel
domain and is responsible for dimerization, essential for enzyme activity [21].
Most PRMTs methylate arginine residues localized within glycine- and arginine-rich (GAR)
sequences, but there are exceptions to this rule [24]. For instance, PRMT4 cannot methylate
GAR motifs, and PRMT5 methylates both GAR and non-GAR motifs. Other factors, such as
the accessibility of the target arginine and the conformation of the involved sequence, also
govern substrate methylation.
PRMT1 was the first mammalian PRMT to be cloned [25] and is the predominant type I en‐
zyme [26] found in all embryonic and adult tissues examined so far [27]. Due to alternative
splicing, there are seven isoforms of the protein, all varying in their N-terminal domain,
which are expressed in a tissue-specific manner and have distinct subcellular localization
patterns [28]. PRMT1 has broad substrate specificity with over 40 targets, most being RNA
processing proteins, and multiple interacting partners [29]. Targeted PRMT1 knockout in
mice results in embryonic lethality, thus showing that loss of PRMT1 activity is incompati‐
ble with life [30].
PRMT2 transcripts have been found in most human tissues, with highest levels in heart,
prostate, ovary and neuronal system [10, 31]. PRMT2 was found predominantly in the nu‐
cleus and to a lower degree in the cytoplasm of mammalian cells [17]. Only recently, based
on the observation that it catalyzes the formation of MMA and ADMA residues on histone
H4, PRMT2 was recognized as a type I enzyme [32]. PRMT2 may act in cooperation with
PRMT8, since its SH3 domain binds the N-terminal domain of the latter enzyme [33]. Some
of the known targets of PRMT2, besides the aforementioned histone H4 [32], are the STAT3
(signal transducer and activator of transcription 3) protein [34], the estrogen receptor alpha
[35], the androgen receptor [31], the retinoblastoma gene product [36], and the heterogene‐
ous nuclear ribonucleoprotein (hnRNP) E1B-AP5 [37]. In contrast with PRMT1 knockouts,
PRMT2 null mice are viable and grow normally [34].
PRMT3 was first identified as a PRMT1-binding partner. It is widely expressed in human
tissues and has a predominantly cytosolic subcellular localization [9]. PRMT3 possesses a
zinc finger domain that assists in its binding to ribosomal proteins, including the S2 protein
of the small ribosomal subunit. Mouse embryos with a targeted disruption of PRMT3 are
small in size but survive after birth and attain a normal size in adulthood [38].
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PRMT4, or CARM1, was first identified as a steroid receptor coactivator [11], providing the
first evidence that protein arginine methylation participates in the regulation of gene expres‐
sion (please, see sections 3.2.1 and 3.2.2.1.). PRMT4 is ubiquitously expressed, exhibits a nu‐
clear localization, and presents restricted substrate specificity. Specifically, in addition to
nuclear hormone receptors and histones, it targets splicing factors [39, 40] and ATP-remod‐
eling factors [41]. As opposed to most PRMTs, and as already referred, PRMT4 does not
methylate GAR sequences. PRMT4 participates in many biological processes, including ear‐
ly T cell development [42], adipocyte differentiation [43], endochondral ossification [44], and
proliferation and differentiation of pulmonary epithelial cells [45]. Embryos of PRMT4 null
mice are small in size and die perinatally, thus showing the importance of PRMT4 activity to
life [46].
PRMT5 was the first PRMT type II to be identified. PRMT5 is widely expressed in mammals,
and more extensively in heart, muscle and testis [12]. PRMT5 is located both in the nucleus
and in the cytoplasm [47]. Interestingly, PRMT5 is localized in the Golgi apparatus (GA) and
its loss disrupts the GA structure, thereby suggesting that this enzyme plays a role in the
maintenance of GA architecture [47]. In addition, PRMT5 is involved in the maintenance of
the spliceosome integrity [48, 49]. PRMT5 targets histones, transcriptional elongation factors,
chromatin remodelers and co-repressors [50]. In mice, loss of PRMT5 results in early embry‐
onic lethality [51].
PRMT6 is the smallest family member (316 amino acids) and is localized predominantly
in the nucleus [13]. Little is known about its properties, besides the fact that it produces
asymmetrically  dimethylated  arginine  residues.  Similarly,  PRMT6  functions  are  not
completely understood. However, a role for PRMT6 in the regulation of cell proliferation
and  senescence,  through  transcriptional  repression  of  tumor  suppressor  genes,  has  just
been reported [52].
PRMT7 is present mainly in thymus, dendritic cells and testis [15, 53]. It has both nuclear
and cytosolic localizations [15]. PRMT7 is involved in the modulation of sensitivity to DNA
damaging agents [54, 55], methylation of male germline imprinted genes [56], and embryon‐
ic stem cell pluripotency [57]. Although Lee and colleagues characterized PRMT7 as a type
II enzyme capable of forming SDMA [15], this finding was recently contested. In fact, Zuri‐
ta-Lopez and coworkers have just reported that PRMT7 produces exclusively MMA resi‐
dues, constituting the sole mammalian PRMT member with this type of methyltransferase
activity [58].
PRMT8 is the type I PRMT with the highest degree of homology with PRMT1, but, unlike
the latter, is mostly found in brain [14, 33]. PRMT8 possesses a myristoylation motif at its N-
terminal end, which facilitates electrostatic interactions with membrane lipids and renders
its distinct plasma membrane localization [14, 33]. Interestingly, its activity is regulated by
the conformation of its N-terminal end, and removal of this domain results in enhancement
of its enzymatic activity [33]. PRMT8 targets the pro-oncoprotein encoded by the Ewing sar‐
coma (EWS) gene, which contains a GAR motif in its C-terminal terminus [59].
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PRMT9 was  identified  as  a  putative  arginine  methyltransferase  and was  classified  as  a
type  II  PRMT  due  to  its  ability  to  catalyze  the  formation  of  MMA  and  ADMA  [16].
However, there is limited sequence homology between PRMT9 and other human PRMTs
[17]. Like most of the PRMTs, PRMT9 is widely expressed in mammalian tissues. PRMT9
has  both  nuclear  and  cytoplasmatic  localization  [17].  Several  PRMT9  isoforms  are
recognized  and  alternate  splicing  may  be  an  important  mechanism  to  regulate
methylation by PRMT9 [16].  So far,  the only known substrates  for  PRMT9 are histones,
the maltose binding protein and several peptides [16].  Disruption of the PRMT9 activity
has  been  associated  with  inflammation  of  the  middle  ear,  indicating  the  importance  of
methylation in disease [60, 61].
PRMT10 and PRMT11 were identified by their homology with PRMT7 and PRMT9, respec‐
tively, but, as referred to above, their PRMT activity has not been sustained by experimental
evidence.
3. Physiological roles of protein arginine methylation
Following the advent of improved sensitivity conquered with mass spectrometry, current
proteomic technologies have been uncovering an increasingly large fraction of the human
proteome as substrates for PRMTs. Additionally, advances in molecular biology techniques
and the generation of mice with targeted deletion of the various members of the PRMTs
family have been disclosing the functional relevance of this PTM. As new substrates are be‐
ing characterized, a broadening spectrum of PRMT-regulated cellular processes is being re‐
alized. So far, targeted cellular processes can be loosely categorized in RNA processing,
transcriptional regulation, DNA repair and signal transduction.
3.1. RNA processing
Most proteins targeted by PRMTs are RNA-binding proteins (RBPs) harboring GAR motifs,
which are involved in all aspects of RNA metabolism [29]. During eukaryotic transcription,
RBPs associate with the nascent pre-mRNA allowing a series of RNA processing events to
take place, including 5’-end capping, splicing, 3’-end cleavage and polyadenylation [62].
The importance of protein arginine methylation for RNA processing was first revealed by
the observation that in HeLa cells splicing reactions were completely inhibited by a pan
SDMA-specific antibody [63]. Subsequent studies have shown that a number of spliceoso‐
mal proteins are subject to both asymmetrical and symmetrical dimethylation, uncovering
the crucial role of protein arginine methylation in the assembly of the spliceosome [64-66].
Other RBPs (hnRNP1, fibrillarin, nucleolin, HuD and HuR) have also been shown to contain
methylated arginine residues [67-70]. Importantly, several of these RBPs lack proper subcel‐
lular localization if hypomethylated [71, 72]. For instance, asymmetrical dimethylation of
specific arginine residues comprising the nuclear poly(A) binding protein prevents its trans‐
port to the cytoplasm [73].
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3.2. Transcriptional regulation
Protein arginine methylation was initially detected in histones and studied mainly in relation to
transcriptional regulation. More recently, the presence of methylated arginines in a large num‐
ber of non-histonic proteins that also impact on transcriptional regulation was recognized.
3.2.1. Histone arginine methylation
Methylation of histones at arginine residues has been very well documented and subject to
periodic review [74-76]. Therefore, a comprehensive review of histone arginine methylation
would go beyond the scope of this paper and will be depicted in general terms only.
A few arginine residues within the N-terminal tail of histones H3, H4 and H2A are subject
to methylation. The N-terminal tail of histone H3 contains several arginine residues that are
targeted by different PRMTs,1 while only one residue in histone H4 (H4R3) is subject to argi‐
nine methylation.2 Since the first residues of the N-terminal tails of histones H4 and H2A are
identical, residue 3 of histone H2A may be methylated in the same manner as H4R3 [76].
Interestingly, histone asymmetrical dimethylation generally activates gene transcription,
while generation of SDMA is normally a repressive mark, although exceptions to this rule
exist [75]. Arginine methylation occurring in histone tails may either affect other PTMs or
influence the docking of key transcriptional effector molecules [76].
3.2.2. Arginine methylation of non-histonic proteins
In addition to histones, PRMTs also target other proteins that are involved in the transcrip‐
tional control of gene expression in mammals. These proteins include several types of tran‐
scription factors, transcription elongation factors, methyl DNA-binding proteins, and RNA
polymerase II, as presented in the following sub-sections. In each, we choose to use some
illustrative examples, rather than present an exhaustive list of all non-histonic targets for
PRMTs that impact transcriptional regulation.
3.2.2.1. Transcription factors
Transcriptional coregulators are well recognized targets of PRMTs. Methylation of nuclear
hormone receptors (NRs) illustrate well how arginine methylation of transcriptional coregu‐
lators may affect gene transcription. NRs are a large group of structurally related transcrip‐
tion factors that are responsible for mediating the biological effects of hormones.
Transcription activation by NRs is a multistep process involving transcriptional coactivator
proteins, as CREB-binding protein (CBP) and p300. These two co-activators have similar
structures, sharing one N-terminal KIX domain that displays several arginine residues that
are subject of methylation by PRMT4 [83]. CBP/p300 exhibits HAT (histone acetyl transfer‐
1 In histone H3, residues 17 (H3R17) and 26 (H3R26) are methylated by PRMT4 [77], H3R2 is methylated by PRMT6
[78], and H3R8 is methylated by PRMT5 [79].
2 In histone H4, one arginine residue (H4R3) is subject to methylation. Asymmetric dimethylation of this residue is
catalyzed by PRMT1, PRMT6 and PRMT8 [80-82], while symmetric dimethylation is catalyzed by PRMT5 and PRMT7
[56, 79].
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ase) and HMT (histone methyl transferase) activities. Both CBP/p300 and PRMT4 are recruit‐
ed to DNA by the NR bound to its ligand, where they stimulate transcription by remodeling
chromatin through subsequent histone acetylation and methylation in the vicinity of hor‐
mone response element (HRE). Notably, it was shown that CBP/p300 activates NR-depend‐
ent gene transcription only if methylated in their KIX domain [83].
Peroxisome proliferator-activated receptor-gamma coactivator (PGC) 1 alpha (PGC-1α) is
other example of a coactivator of NRs whose activity was clearly shown to be dependent on
PRMT activity. PGC-1α signaling is extremely important in the heart, where PGC-1α is
highly expressed and controls cardiac energy pathways during development and in re‐
sponse to stressors. Interestingly, it was shown that PRMT1 activates PGC-1α through its
methylation at several arginine residues [84]. Remarkably, experimentally based evidence
has recently linked decreased levels of methyl-PGC-1α due to decreased PRMT1 activity to
cardiomyopathy in mice [85].
Arginine methylation may also impact transcriptional activity by targeting transcription fac‐
tors that bind directly to DNA, like the STAT1 protein. STAT1 (signal transducer and activa‐
tor of transcription) is a member of the STAT family and mediates the cellular response to
cytokines and growth factors thus regulating many aspects of growth, survival and differen‐
tiation of cells. After activation by cytoplasmic phosphorylation, STAT1 migrates to the nu‐
cleus, where it binds to the enhancer elements of response genes. The N-terminal region of
STAT1 comprises a conserved arginine residue that was shown to be a PRMT1 target [86].
Inhibition of PRMT1 activity hinders the DNA binding activity of STAT1 and STAT1-medi‐
ated transcription.
3.2.2.2. Transcription elongation factors
Activity of PRMTs may also affect transcription by marking transcription elongation factors,
like Spt5. The Spt5 protein displays several KOW domains, which contain consensus sites
for arginine methylation and overlap the RNA polymerase II binding domain. Notably, Spt5
can be methylated in its RNA polymerase II binding domain by PRMT1 or PRMT5 and this
methylation may cause transcriptional pausing [87].
3.2.2.3. Methyl DNA-binding proteins
PRMTs may also participate in the DNA methylation system of chromatin control. DNA
methylation, an important regulator of gene transcription, occurs within a CpG context in
differentiated mammalian cells. MBD2 is a methyl DNA-associated protein that docks me‐
thylated CpGs in DNA and negatively affects gene transcription by recruiting proteins that
repress chromatin. Interestingly, both PRMT1 and PRMT5 methylate MBD2, thereby impair‐
ing the transcription repression function of MBD2 [88].
3.2.2.4. RNA polymerase II
In eukaryotic cells, the C-terminal domain (CTD) of RNA polymerase II provides a platform
to recruit different regulators of the transcription apparatus. Recently, arginine methylation
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of a single residue in the CTD (R1810) was documented and implied in the regulation of
transcription driven by RNA polymerase II [89].
3.3. DNA repair
Genome  integrity  is  constantly  subject  to  monitoring  by  a  complicated  and  entangled
network of mechanisms collectively termed as DNA damage response (DDR). Some pro‐
teins  integrating  this  system are  known targets  of  PRMTs.  Mre11  is  part  of  a  complex
that  is  critically  implicated in  homologous  recombination  repair  of  DNA double  strand
breaks. This protein harbors a GAR motif that is methylated by PRMT1, allowing its as‐
sociation with nuclear  structures  and recruitment  to  sites  of  DNA damage [90],  as  well
as its  exonuclease activity [91].  PRMT5-induced methylation of Rad9,  a cell  cycle check‐
point protein,  enables activation of Chk1,  an important downstream checkpoint effector,
and loss of Rad9 methylation leads to S/M and G2/M checkpoint defects [92]. DNA poly‐
merase  beta,  which participates  in  DNA base  excision repair,  is  methylated by PRMT6,
which enhances its binding to DNA and its processivity [93].
3.4. Signal transduction
In addition to regulating numerous nuclear processes, arginine methylation is involved in
conveying information from the cell surface, through the cytoplasm, to the nucleus. For in‐
stance, the implication of protein arginine methylation in interferon (IFN) signaling has been
substantiated by the fact that PRMT1 interacts with the cytoplasmic domain of the type I
IFN receptor [94], and that its depletion impairs the biological activity of type I IFN [95]. The
involvement of arginine methylation within T cell receptor signaling cascades is also gaining
prominence. In fact, stimulation of T helper cells induces arginine methylation of several cy‐
toplasmic proteins, which when inhibited causes signaling defects in CD4 T cells and severe
immunosuppression [96]. PRMT1-mediated methylation also impacts insulin signaling and
glucose uptake in skeletal muscle cells [97]. Estrogen rapid signaling is similarly mediated
by PRMT1, which targets estrogen receptor alpha (ER-α) [98]. PRMT1 also methylates
FoxO1, a member of the mammalian forkhead transcription factors of class O (FoxO) sub‐
family [99]. These transcription factors are involved in many vital processes (e.g. apoptosis,
cell-cycle control, glucose metabolism, oxidative stress resistance and longevity) and, in re‐
sponse to insulin or several growth factors, are negatively regulated through phosphoryla‐
tion by serine-threonine kinase Akt/protein kinase B (Akt/PKB) (that results in their export
from the nucleus to the cytoplasm) [100]. PRMT1 methylates FoxO1 at arginine residues
within the Akt consensus motif, blocking the Akt-mediated phosphorylation and augment‐
ing FoxO1 target gene expression [99]. Another Akt-target protein is BCL-2, antagonist of
cell death, which is also methylated by PRMT1 on its consensus phosphorylation motif
[101]. Methylation-phosphorylation switches are presently regarded as paradigms operating
in signal transduction pathways and other physiological processes, since numerous other
examples of this crosstalk have been described. The implication of PRMTs other than
PRMT1 in signaling routes has not been well studied. The association of PRMT8 with the
plasma membrane provides a clue that this enzyme may facilitate the triggering of a signal‐
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ing pathway [14]. A recent study has uncovered that PRMT5 regulates the amplitude of the
RAS to extracellular signal-regulated kinase (ERK) signal transduction cascade, impacting
on cell fate decision [102].
4. Modulation of PRMTs activity
PRMTs associate with proteins that may change their activity or substrate specificity. Exam‐
ples of proteins that enhance the activity of a specific PRMT are: BTG1 (B-cell translocation
gene 1 protein), BTG2 (B-cell translocation gene 2 protein) and hCAF1 (chemokine receptor
4-associated factor 1), which associate with PRMT1 [25, 103]; the chromatin remodelers BRG
and BRM, which enhance PRMT5 activity [79]; and BORIS (brother of the regulator of im‐
printed sites), which has been reported to elevate PRMT7 activity [56]. In contrast, tumor
suppressor DAL-1 inhibits the activity of PRMT3 in vitro and in vivo [104]. PRMT4 associa‐
tion with other proteins within the nucleosomal methylation activator complex (NUMAC)
enhances its ability to methylate nucleosomal histone H3, while the free enzyme preferen‐
tially methylates free core histone H3 [41]. Similarly, PRMT5 association with COPR5 shifts
its preferential target from H3R8 to H4R3 [105].
PRMT activity may also be modulated by PTMs. For instance, several PRMTs are autome‐
thylated, but the relevancy of this phenomenon is not acquainted [33]. PRMT4 phosphoryla‐
tion during mitosis prevents its homodimerization, thereby decreasing its activity [106].
Additionally, PRMT4 phosphorylation abolishes the binding of AdoMet and thus its activi‐
ty, and promotes its cytoplasm localization [107].
5. The reversibility of protein arginine methylation: A fast-growing field
of knowledge
An important question under recent investigation was whether demethylation reactions oc‐
curred to reverse the effects of protein arginine methylation. Initial studies indicated that
this PTM was a permanent mark on proteins. As such, the only way to reverse the effects of
the presence of this methyl mark would be to degrade the protein to its amino acid compo‐
nents and then make a new unmethylated version by protein synthesis [108]. However, the
long-standing notion that arginine methylation is a stable covalent mark has been chal‐
lenged in recent years due to the discovery of two types of enzymes that can remove methyl
groups from arginine residues in histones by demethylation and citrullination (Figure 3).
The first evidence of demethylation of arginine residues came from a study by Chang and
coworkers [110] that reported that JMJD6, a Jumonji domain-containing protein, demethy‐
lates H3R2 and H4R3 residues that are either asymmetrically or symmetrically dimethylated
(Figure 3A). Mass spectrometry of a peptide containing dimethylated arginine residues,
which was incubated with JMJD6 and then immunoprecipitated with a monomethylargi‐
nine specific antibody, revealed that the enzyme catalyzed the loss of one methyl group
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from the methylated substrate. Current view holds that JMJD6 may be a bifunctional en‐
zyme, catalyzing either demethylation or lysyl-hydroxylation reactions [111].
Figure 3. Reversing or annulling protein arginine methylation: demethylation and citrullination reactions. (A) Deme‐
thylation of a monomethylarginine (MMA) residue by JMJD6. (B) Citrullination of a MMA residue by PAD4. This reac‐
tion antagonizes arginine methylation, since it is not reversible. Adapted from [109].
Monomethylated  arginine  residues  may  be  converted  to  citrulline  by  deimination,  a
modification  catalyzed  by  peptidylarginine  deiminases  (PADs).  In  this  process,  the
guanidinium side chain of  an arginine residue is  hydrolyzed and methylamine released
[112]  (Figure  3B).  To  date,  five  human  PAD  homologs  have  been  identified  and
designated  as  PAD1-4  and  PAD6.  Most  mechanistic  studies  on  PADs  have  been
performed with PAD4. PADs may be activated by calcium, which seems to be essential
for  the  catalysis  to  occur  [113,  114].  Citrulline  residues  are  found  with  great  extent  in
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histones H2A, H3, and H4 [115].  Importantly, the sites of deimination by PAD4 overlap
those of arginine methylation on these histones [112], and an increase in histone citrulline
levels correlates with a decrease in methylated arginine levels [116, 117]. However, PADs
only catalyze the deimination of MMA residues, and no enzyme has been identified that
can convert citrulline back to arginine. Thus, citrullination blocks remethylation, adding a
new layer to the regulation of protein arginine methylation [118, 119].
6. The disposal of methylated arginine residues / ADMA and vascular
disease
Proteolysis of arginine-methylated proteins results in free MMA, ADMA and SDMA, which
are secreted to the extracellular space [120]. These metabolites can then be taken up by other
cells via carriers of the cationic amino acid family [121] or eliminated by renal excretion
[122]. In addition, ADMA can be hydrolyzed to citrulline and dimethylamine, by dimethy‐
larginine dimethylaminohydrolase (DDAH), which is present in kidney, liver and vascula‐
ture [123]. Interestingly, MMA and ADMA are endogenous inhibitors of nitric oxide (NO)
production in endothelial cells. Due to the paramount role of NO on the homeostasis of the
vascular endothelium, ADMA, which is present in plasma in much larger quantities than
MMA, has emerged as a novel risk factor in the setting of endothelial dysfunction and vas‐
cular disease [124]. As stated before, PRMTs are ubiquitously expressed and participate in
crucial cellular processes. Thus, deregulation of these enzymes is likely implicated in the
pathogenesis of a number of different diseases, including cardiovascular disease. In addition
to the intricate set of potential interactions between protein arginine methylation and cardio‐
vascular disease, we must add ADMA, an additional player that may impact the cardiovas‐
cular system.
7. Protein arginine hypomethylation in the context of
hyperhomocysteinemia: “Another brick in the wall”?
As illustrated in Figure 1, the methyl group responsible for the establishment of protein ar‐
ginine methylation patterns by PRMTs originates from AdoMet, an intermediate in the ho‐
mocysteine metabolism. Therefore, protein arginine methylation and homocysteine
metabolism are biochemically linked (Figure 4). In addition to protein arginine methylation,
AdoMet serves as the methyl donor for more than one hundred cellular methyl transfer re‐
actions, including the methylation of other residues in proteins (namely, histidine and ly‐
sine), DNA and RNA. Following the transfer of the methyl group, AdoMet is converted into
S-adenosyl homocysteine (AdoHcy). AdoHcy is further converted into homocysteine and
adenosine by AdoHcy hydrolase, which is widely distributed in mammalian tissues [125].
This reaction is reversible and strongly favors AdoHcy synthesis rather than its hydrolysis;
however, both homocysteine and adenosine are rapidly removed under physiological condi‐
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tions, favoring the hydrolysis reaction [126]. Nevertheless, if homocysteine accumulates,
AdoHcy will accumulate as well [125].
Figure 4. Simplified homocysteine metabolism. Homocysteine (Hcy) results from methionine metabolism as a by-
product of cellular transmethylation reactions. Methionine (Met) is the “entry” point of this pathway and is provided
by diet and protein breakdown. S-Adenosylmethionine (AdoMet) is first synthesized from Met by methionine adeno‐
syltransferase (MAT). AdoMet is the methyl group donor in a wide variety of transmethylation reactions, being con‐
verted to S-Adenosylhomocysteine (AdoHcy). AdoHcy is subsequently hydrolyzed to Hcy and adenosine by AdoHcy
hydrolase. Hcy can then be converted to cysteine (Cys) through the transsulphuration pathway, remethylated back to
methionine or exported.
Despite recent controversy, elevated levels of homocysteine in plasma (or hyperhomocystei‐
nemia) are accepted as a risk factor for cardiovascular disease [127, 128]. Notably, despite
several potential mechanisms underlying this association having been the focus of intense
research, the subject remains to be fully understood [125]. Our group has been actively
studying whether a hypomethylating environment associated with hyperhomocysteinemia
contributes to the vascular toxicity of homocysteine [129-133]. AdoHcy is a competitive in‐
hibitor of most AdoMet-dependent methyltransferases, since it binds to their active sites
with higher affinity than AdoMet [134]. As such, the ratio AdoMet/AdoHcy is taken as an
index of cellular methylation capacity. As mentioned above, if homocysteine accumulates,
AdoHcy will accumulate as well. Thus, increased homocysteine may be regarded as a cellu‐
lar hypomethylation effector, via AdoHcy accumulation.
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We have demonstrated that patients with vascular disease present increased levels of both
plasma homocysteine and intracellular AdoHcy, together with decreased DNA methylation
[129]. Other studies also supported a role for hyperhomocysteinemia in modulating epige‐
netic mechanisms [135-138]. Additionally, we confirmed, in vitro, the AdoHcy ability to de‐
crease global DNA methylation status [131]. Currently, we are studying whether, in
addition to DNA, protein arginine methylation extend is are also decreased by AdoHcy ac‐
cumulation. Supporting this possibility, results from kinetic studies regarding competitive
inhibition of several methyltransferases by AdoHcy sustain that this metabolite is a stronger
inhibitor of PRMT1 than of DNA methyltransferase 1, the enzyme responsible for the main‐
tenance of DNA methylation patterns [6, 139]. Interestingly, we observed that intracellular
AdoHcy accumulation lowered ADMA production by human vascular endothelial cells ac‐
cumulation [133]. This observation led us to postulate that this effect was due to AdoHcy-
induced protein arginine hypomethylation. Supporting this possibility, we subsequently
found decreased levels of protein-incorporated ADMA in human vascular endothelial cells
under AdoHcy intracellular accumulation ([140] and Esse R et al., manuscript 1 under sub‐
mission). Moreover, we observed that this effect was more pronounced than the parallel re‐
duction in global DNA methylation patterns. Therefore, we have concluded that AdoHcy
build-up affects protein arginine methylation to a higher extent than DNA methylation. Im‐
portantly, this observation suggests that protein arginine methylation is more easily affected
than DNA methylation in the context of hyperhomocysteinemia. Very recently, we have also
assessed protein arginine methylation status in an animal model of diet-induced hyperho‐
mocysteinemia and found that increased homocysteine is associated with protein arginine
hypomethylation, although in a tissue-dependent manner ([141] and Esse R et al., manu‐
script 2 under submission). Specifically, we found global protein arginine hypomethylation
in heart and in brain from hyperhomocysteinemic rats, while methylation of hepatic pro‐
teins was not affected. Currently, we are undertaking both in vitro and in vivo studies to
identify proteins sensitive to AdoHcy-induced hypomethylation, and to assess the impact of
its different methylation states on vascular homeostasis. Actually, differential methylation of
proteins may well play a role in pathologies related to elevated homocysteine, including
vascular disease.
8. Conclusions
The  field  of  protein  arginine  methylation  has  been  enjoying  widespread  interest  in  the
scientific  community,  owing to  the recent  development  of  molecular  biology techniques
and mass spectrometry instrumentation.  It  is  now clear  that  this  common PTM impacts
crucial  biological  functions,  including  RNA  processing,  transcriptional  regulation,  DNA
repair  and signal  transduction.  Yet,  information  is  still  scant  regarding  some important
issues  of  protein  arginine  methylation,  namely  its  regulation  by  other  PTMs,  how  it
affects  interaction  with  the  protein  ligands,  and  what  are  the  factors  governing  the
specificity  of  the  different  PRMTs  towards  the  target  protein.  Importantly,  protein
arginine methylation,  which was considered a static  modification during a long time,  is
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now recognized as  a  reversible  and dynamic modification,  increasing the complexity  of
the  interplay  between  DNA,  proteins  and  vital  cellular  process.  Nevertheless,  the
characterization of enzymes that reverse and block protein arginine methylation has just
commenced.  Moreover,  the  pathological  implications  of  protein  arginine  methylation
disturbance have not been exhaustively explored. The methyl group marking of arginine
residues originates from AdoMet, an intermediate in homocysteine metabolism. Thus, the
metabolism of this amino acid and protein arginine methylation are biochemically linked.
Homocysteine  elevation  relates  with  an  increased  risk  of  vascular  disease  and  others
pathologies.  Notably,  the  potential  detrimental  effect  of  increased  circulating
homocysteine  on  protein  arginine  methylation  status  may  constitute  an  additional
molecular  mechanism  contributing  to  disease,  and,  as  such,  warrants  further
investigation.
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